The PHQ-9 (Patient Health Questionnaire-9) is a validated, nine-item instrument used to screen for depression and monitor the severity of depressive symptoms over time. It is the global “gold standard” for depression measurement because it maps directly onto the nine DSM-5 criteria for Major Depressive Disorder, making it an essential tool for Measurement-Based Care (MBC).

Clinical Use: Therapists use the PHQ-9 to establish a baseline at intake and track symptom changes at regular intervals throughout treatment.

The Advantage: It provides an objective, numerical score that helps clinicians and clients visualize progress beyond subjective session check-ins.

The PHQ-9 is scored by assigning a value of 0 (Not at all) to 3 (Nearly every day) to each of the nine items, resulting in a total score between 0 and 27. Higher scores indicate greater symptom severity, with the following standard clinical ranges:

• 0–4: Minimal or no depression
• 5–9: Mild depression
• 10–14: Moderate depression
• 15–19: Moderately severe depression
• 20–27: Severe depression

Question 9 on the PHQ-9 specifically screens for suicidal ideation by asking if the respondent has had thoughts of being better off dead or of hurting themselves. Because this is a critical safety “signal,” any positive response (a score of 1, 2, or 3) requires an immediate, comprehensive suicide risk assessment and follow-up clinical protocol.

• Clinical Alert: While Item 9 is a vital screening tool, research suggests it should not be used as a standalone suicide assessment; it serves as a trigger for a deeper safety conversation.

Yes, the PHQ-9 is highly effective for progress monitoring because its 0–27 scale allows clinicians to see if depressive symptoms are improving, plateauing, or worsening during treatment. When used session-by-session or monthly, the PHQ-9 provides the “hard data” needed for insurance reporting and clinical supervision, ensuring treatment remains responsive to the client’s current state.

A PHQ-9 score of 9 falls at the top of the “Mild Depression” range (5–9) and suggests that while the client may not meet full diagnostic criteria for Major Depressive Disorder, they are experiencing clinically relevant distress. Clinicians typically look at whether the score is rising or falling over time and whether specific items (like sleep or concentration) are significantly impacting the client’s daily functioning.

The PHQ-9 is designed specifically to measure depressive symptoms, while the GAD-7 is designed to measure symptoms of Generalized Anxiety Disorder (GAD). Because depression and anxiety are frequently comorbid, most high-performing clinics administer both tools together to get a comprehensive view of the client’s emotional health and well-being.

The PHQ-9 is one of the most rigorously studied evidence-based tools in mental health, with high sensitivity (88%) and specificity (88%) for detecting major depression. Its reliability across diverse populations in the USA, Canada, and Australia makes it a trusted standard for both private practices and large-scale hospital systems.

Digital PHQ-9 tracking via platforms like MyOutcomes automates the scoring process, creates instant visual trend graphs, and flags “at-risk” scores (like Item 9) for immediate clinician review. This reduces the “administrative burden” of manual scoring and ensures that symptom data is integrated directly into the clinician’s dashboard alongside alliance feedback (SRS) and progress outcomes (ORS).